Atossa Completes Enrollment Of Pharmacokinetic Run-In Cohort In Phase 2 EVANGELINE Clinical Trial Evaluating (Z)-Endoxifen As A Neoadjuvant Treatment For ER+ / HER2- Breast Cancer
Portfolio Pulse from Benzinga Newsdesk
Atossa Therapeutics has completed enrollment of the pharmacokinetic run-in cohort in its Phase 2 EVANGELINE clinical trial, evaluating (Z)-endoxifen as a neoadjuvant treatment for ER+/HER2- breast cancer. The trial aims to determine the optimal dose of (Z)-endoxifen, with data expected in Q3.
June 12, 2023 | 1:16 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Atossa Therapeutics has completed enrollment for its Phase 2 EVANGELINE clinical trial, evaluating (Z)-endoxifen for ER+/HER2- breast cancer, with data expected in Q3.
The completion of enrollment for the Phase 2 EVANGELINE clinical trial is a positive development for Atossa Therapeutics, as it brings the company closer to determining the optimal dose of (Z)-endoxifen for ER+/HER2- breast cancer treatment. Positive data from the trial in Q3 could potentially boost the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100